iOnctura to present research on roginolisib and IOA-359 at ASH

iOnctura Switzerland California

Three abstracts accepted by ASH with two poster presentations is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways such as cellular proliferation; escape from immune detection; and drug resistance. iOnctura's pioneering approach to drug development is expected to offer significant clinical benefits over the traditional approach of targeting a single pathway alone. iOnctura has progressed two therapeutic candidates into mid-stage clinical development: Roginolisib (IOA-244), an allosteric modulator of PI3K?; and IOA-289, a highly selective, non-competitive autotaxin (ATX) inhibitor. IOA-359, a TGF–? pathway inhibitor is also undergoing an extensive pre-clinical program in preparation for first-in-human studies. iOnctura is backed by specialist institutional investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. iOnctura BV is headquartered in Amsterdam, The Netherlands with its wholly owned Swiss subsidiary, iOnctura SA, located in Geneva, Switzerland.

About roginolisib

Roginolisib (IOA-244) is a first-in-class small molecule allosteric modulator of PI3K?. Its unique structural and selectivity features drive a unique way of inhibiting PI3K? which translates into a highly beneficial tolerability and clinical benefit profile. PI3K? over-expression stimulates multiple cancer mechanisms and has an oncogenic role in many tumor types.  Roginolisib has a multi-modal effect on cancer; directly preventing cancer cell proliferation, harnessing an anti-tumor immune response via an effect on regulatory T-cells and cytotoxic T cells and potentiating the effect of immunotherapy. Roginolisib is currently in the extension phase of the DIONE-01 trial, a two-part, first-in-human dose study evaluating the drug in advanced cancers and as a combination partner for conventional and immune-therapies (NCT04328844).

About IOA-359

IOA–359 is a novel oral TGF–? pathway inhibitor that will be evaluated in solid tumors. Activation of the TGF-? signaling pathway in tumors correlates with tumor aggressiveness, immune escape and resistance to therapy, making it an attractive target for cancer therapy. The inhibition of TGF-? signaling with IOA-359 is expected to attenuate cancer progression through direct effects on cancer, immune and stromal cells. By characterising the resistance mechanisms that typically arise when targeting the TGF-? pathway alone, iOnctura's data-driven precision oncology methods are being used to design novel combination treatments that promise to override tumor survival pathways.

View original content:https://www.prnewswire.co.uk/news-releases/ionctura-to-present-research-on-roginolisib-and-ioa-359-at-ash-301976329.html